Bristol-Myers Squibb Pension Plan

Bristol-Myers Squibb Pension Plan

Bristol-Myers Squibb Pension Plan is the US defined-benefit vehicle for the global biopharma company, which traces its roots to the 1887 Bristol-Myers Company and the 1858 E.R. Squibb & Sons. The plan covers legacy US employees and retirees, operating under the fiduciary framework of ERISA with oversight by an internal benefits investment committee. Unlike a family office or endowment, its mission is strictly to fund accrued benefit obligations, which shapes every allocation decision. The plan's portfolio anchors in investment-grade fixed income and long-duration corporate credit — the natural match for its liability stream. Public equities form the next-largest sleeve, accessed primarily through external managers across US large-cap, developed international, and emerging markets. Alternatives exposure typically includes private equity fund commitments, opportunistic real estate, and hedge fund allocations structured as part of a risk-mitigation framework. The plan also maintains exposure to Treasury inflation-protected securities and real assets as an inflation hedge. Geographic footprint is concentrated in US markets, with developed-market international exposure through commingled vehicles. Bristol-Myers Squibb closed its primary US pension plan to new entrants years ago and has executed a series of derisking moves consistent with large corporate peer practice, including a well-publicized annuity buyout. In July 2019, the company purchased a group annuity contract from Athene Holding to transfer approximately $1.8 billion in pension obligations, covering roughly 24,000 retirees and beneficiaries (per Reuters, 2019). Following the company's acquisition of Celgene, it also assumed responsibility for legacy Celgene pension obligations, integrating those liabilities into its existing plan framework. The plan's current deployment size is not publicly itemized in the company's SEC filings as a discrete AUM figure distinct from the broader benefit obligation. The structural differentiator is the plan's position inside a highly acquisitive, innovation-driven pharmaceutical enterprise. Liability management does not happen in isolation — it competes for treasury attention with M&A, R&D expenditure, and capital return programs. The 2019 Celgene acquisition brought in new liabilities at scale, and subsequent asset-liability integration work likely reshaped the portfolio's duration and credit mandates. This makes the plan a case study in pension management inside a balance-sheet-intensive corporation where the pension deficit or surplus moves the CFO's leverage ratios.